Click on image to view larger version.

Figure 4 Divergence in platelet inhibition with abciximab with increasing time. Divergence in platelet inhibition with increasing infusion duration (52). Late variation in platelet inhibition may contribute to increased periprocedural events as seen in CAPTURE when compared with EPIC, EPILOG and EPISTENT. CAPTURE = C7E3 FAB Anti Platelet Therapy in Unstable Refractory Angina; EPIC = Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG = Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa blockade; EPISTENT = Evaluation of IIb/IIIa Platelet Inhibitor for Stenting.